2C-B Shows Empathogenic and Psychedelic Effects with Low Cardiovascular Strain

The resurgence of interest in psychedelic-assisted therapy has primarily focused on psilocybin and 3,4-methylenedioxymethamphetamine (MDMA) for treating treatment-resistant depression and posttraumatic stress disorder [1, 2]. While these compounds show efficacy in modulating neural networks and promoting neuroplasticity (the brain's ability to reorganize itself by forming new neural connections), their clinical utility is often constrained by long durations of action and significant autonomic stimulation [3, 4]. Clinicians are increasingly evaluating a broader range of phenethylamines (a class of compounds with stimulant and hallucinogenic properties) to identify molecules with improved safety or logistical profiles [5, 6, 7]. Among these, 4-bromo-2,5-dimethoxyphenethylamine (2C-B) has gained attention as a substance that may bridge the gap between the empathogenic (emotion-enhancing) effects of MDMA and the hallucinogenic properties of classic psychedelics [8, 9]. A new double-blind, placebo-controlled study comparing 30 mg of 2C-B, 125 mg of MDMA, and 25 mg of psilocybin now provides a rigorous comparison to clarify the potential role of 2C-B in the clinical setting [10].